Maha Katabi

Maha Katabi (board member) discloses dealings in 3 companies, chiefly Vera Therapeutics, Inc., RayzeBio, Inc. and Jade Biosciences, Inc. In total, 17 filings cover trades dated from 18 May 2021 to 25 March 2024.

Both buying and selling appear: 5 purchases worth €23.3M, against 6 sales worth €31.4M. Taken together, the sales exceed the purchases by €8.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2024 alone, the filings show 1 purchase and 6 sales.

Half of the purchases are above €4.2M and half below. 3 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 25 March 2024, the filings show an open-market sale worth €12.7M in Vera Therapeutics, Inc. The most recent open-market purchase was published on 1 February 2024, 996 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.